American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

Lexicon Pharmaceuticals, Inc.

LXRX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

LXRX historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of LXRX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
LXRX Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
LXRX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
LXRX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in LXRX holdings by institutional investors

Insider Trading

Quarterly net insider trading by LXRX's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $40,000 Apr 17, 2020 Issue: Pharmacy
Revolving Door

Former government officials who have lobbied for LXRX

3 former government officials from 2 congressional offices at 1 lobbying firm have lobbied for LXRX, most recently Apr 18, 2020.

  • Kathleen Mcauliffe House Counsel, House Democratic Leader Richard Gephardt 95-2000 Formerly Counsel, House Democratic Leader Richard Gephardt 95-2000 · HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP) · Apr 18, 2020
  • Orrin G. Hatch
    Michael Bell Senate Special Asst to the Atty Gen - Legislative Affairs-DOJ (2003-2005); Dpty Assoc. Dir for Presidential Personnel-The White House (2001-2003); Staff Member-Sen Orrin G. Hatch (2000-2001); Staff Asst-US Senate, Comm on the Judiciary (1998-2000) Formerly with Orrin G. Hatch · HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP) · Apr 18, 2020
  • Tony Cárdenas
    Katherine Pereira King House Legislative Assistant, Congressman Tony Cardenas, 2013 - 2017 Formerly with Tony Cárdenas · HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP) · Apr 18, 2020
Corporate Lobbying

LXRX Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
Revenue Breakdown

LXRX Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
LXRX Income Statement
LXRX Balance Sheet
LXRX Cash Flow
U.S. Patents

New LXRX patent grants

  • Patent Title: Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use Jan. 09, 2018
  • Patent Title: Inhibitors of sodium glucose cotransporter 1 Jun. 27, 2017
  • Patent Title: Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use Jun. 20, 2017
  • Patent Title: 4h-thieno[3,2-c]chromene-based inhibitors of notum pectinacetylesterase and methods of their use Apr. 18, 2017
  • Patent Title: Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use Aug. 02, 2016
  • Patent Title: Sodium glucose co-transporter inhibitors and methods of their use Jun. 14, 2016
  • Patent Title: Inhibitors of sodium glucose cotransporter 1 Dec. 01, 2015
  • Patent Title: Methods of treating diabetes Jun. 30, 2015
  • Patent Title: Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use Mar. 03, 2015
  • Patent Title: Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use Feb. 03, 2015
  • Patent Title: Solid forms of (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid Jul. 08, 2014
  • Patent Title: 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use Jul. 08, 2014
  • Patent Title: Multicyclic compounds and methods of their use Jul. 08, 2014
  • Patent Title: Monoclonal antibodies against angptl3 Jun. 03, 2014
  • Patent Title: Solid forms of 3-(4-(aminomethyl)-1-(5-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate May. 27, 2014
  • Patent Title: (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone dihydrate and methods of its use Feb. 25, 2014
  • Patent Title: Solid forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use Feb. 18, 2014
  • Patent Title: Tryptophan hydroxylase inhibitors Jan. 14, 2014
  • Patent Title: Monoclonal antibodies against angptl4 Nov. 26, 2013
  • Patent Title: Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds Nov. 05, 2013
  • Patent Title: Substituted pyrrolo[2,3-d]pyrimidines as lim kinase 2 inhibitors Aug. 13, 2013
  • Patent Title: Sulfanyl-tetrahydropyran-based compounds and methods of their use Jul. 02, 2013
  • Patent Title: Compounds useful in the preparation of tryptophan hydroxylase inhibitors May. 28, 2013
  • Patent Title: Limk2 inhibitors, compositions comprising them, and methods of their use May. 28, 2013
  • Patent Title: Mst1 kinase inhibitors and methods of their use May. 14, 2013
  • Patent Title: Methods of treating pulmonary hypertension Apr. 02, 2013
  • Patent Title: Methods of treating ulcerative colitis Mar. 26, 2013
  • Patent Title: Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors Oct. 23, 2012
  • Patent Title: Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use Jul. 10, 2012
  • Patent Title: Solid forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1- (4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use Jun. 05, 2012
  • Patent Title: Limk2 inhibitors, compositions comprising them, and methods of their use Jun. 05, 2012
  • Patent Title: Aryl pyridines and methods of their use Apr. 10, 2012
  • Patent Title: Methods of using and compositions comprising tryptophan hydroxylase inhibitors Jan. 10, 2012
  • Patent Title: Methods of preparing imidazole-based compounds Jan. 10, 2012
  • Patent Title: Methods of treating rheumatoid arthritis Jan. 10, 2012
  • Patent Title: O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer Jan. 10, 2012
  • Patent Title: 4-amino-1h-pyrimidin-2-one based compounds, compositions comprising them and methods of their use Jan. 10, 2012
  • Patent Title: Monoclonal antibodies against angptl4 Jan. 10, 2012
  • Patent Title: Multicyclic amino acid derivatives and methods of their use Nov. 22, 2011
  • Patent Title: Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors Sep. 27, 2011
  • Patent Title: Solid forms of (1r,2s,3r)-1-(2-(isoxazol-3-yl)-1h-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use Aug. 16, 2011
  • Patent Title: 1-phenyl-1h-pyrazole-based compounds Jun. 28, 2011
  • Patent Title: Methods of preparing imidazole-based bicyclic compounds Jun. 28, 2011
  • Patent Title: Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds Jun. 28, 2011
  • Patent Title: Process for preparing 5-alkyl-7h-pyrrolo[2,3-d] pyrimindine-2-ols May. 31, 2011
  • Patent Title: Monoclonal antibodies against angptl3 May. 03, 2011
  • Patent Title: Synthesis of piperazines, piperidines and related compounds Apr. 05, 2011
  • Patent Title: Process for the preparation of substituted phenylalanines Mar. 01, 2011
  • Patent Title: Methods and compositions for treating pulmonary hypertension and related diseases and disorders Jan. 25, 2011
  • Patent Title: Process for the preparation of substituted phenylalanines Dec. 21, 2010
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to LXRX from public contracts

LXRX News

Recent insights relating to LXRX

CNBC Recommendations

Recent picks made for LXRX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in LXRX

LXRX Analyst Ratings

LXRX Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
LXRX Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $LXRX stock a Buy, Sell, or Hold?

  • What is the price target for $LXRX stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

LXRX Top Shareholders
Shareholder
Shares Held
LXRX Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $LXRX stock?

  • Who owns the most shares of $LXRX stock?

  • What funds own $LXRX stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

LXRX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view LXRX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About LXRX

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

  • Address The Woodlands, TX
  • Market Cap 827.6 million
  • Employees 81
  • Industrial Classification Pharmaceutical Preparations

Lexicon Pharmaceuticals, Inc. (LXRX) Historical Stock Prices

Lexicon Pharmaceuticals, Inc. (LXRX) closed at $1.86 on September 24, 2026. Over the past year its adjusted close ranged from $1.14 to $2.64. Daily prices go back to January 2, 2014, 3,199 trading days in all.

  • 1 month-20.51%
  • 3 months-18.78%
  • Year to date+61.74%
  • 1 year+39.85%
  • 3 years+75.47%
  • 5 years-62.35%
  • Max-85.16%
See every congressional and insider trade on the LXRX price chart

Quiver Premium charts LXRX's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 24, 2026 2.05 2.06 1.85 1.86 1.86 4,441,760
Sep 23, 2026 2.17 2.17 2.02 2.06 2.06 3,172,480
Sep 22, 2026 2.05 2.19 2.02 2.18 2.18 4,843,826
Sep 21, 2026 2.05 2.08 2.00 2.04 2.04 2,506,460
Sep 18, 2026 2.04 2.06 1.99 2.05 2.05 7,458,743
Sep 17, 2026 2.05 2.11 2.02 2.04 2.04 2,235,727
Sep 16, 2026 2.01 2.06 2.00 2.02 2.02 2,151,590
Sep 15, 2026 1.98 2.02 1.89 2.01 2.01 2,508,532
Sep 14, 2026 1.97 2.01 1.94 1.98 1.98 1,773,837
Sep 11, 2026 2.05 2.06 1.95 2.00 2.00 3,726,759
Sep 10, 2026 2.11 2.14 2.01 2.02 2.02 2,938,740
Sep 9, 2026 2.21 2.23 2.13 2.15 2.15 2,204,341
Sep 8, 2026 2.22 2.25 2.19 2.23 2.23 1,657,041
Sep 4, 2026 2.25 2.25 2.21 2.24 2.24 1,044,611
Sep 3, 2026 2.25 2.27 2.23 2.26 2.26 1,510,144
Sep 2, 2026 2.21 2.27 2.19 2.24 2.24 2,335,861
Sep 1, 2026 2.24 2.27 2.17 2.19 2.19 1,987,900
Aug 31, 2026 2.27 2.29 2.19 2.25 2.25 6,653,031
Aug 28, 2026 2.30 2.32 2.26 2.29 2.29 2,679,263
Aug 27, 2026 2.30 2.34 2.29 2.32 2.32 1,618,340
Aug 26, 2026 2.32 2.35 2.28 2.31 2.31 1,200,274
Aug 25, 2026 2.35 2.37 2.30 2.34 2.34 1,821,248
Aug 24, 2026 2.32 2.35 2.29 2.32 2.32 1,675,637
Aug 21, 2026 2.19 2.31 2.19 2.30 2.30 3,194,807
Aug 20, 2026 2.40 2.40 2.17 2.18 2.18 4,746,460
Aug 19, 2026 2.46 2.48 2.39 2.41 2.41 1,776,304
Aug 18, 2026 2.33 2.44 2.33 2.42 2.42 2,904,994
Aug 17, 2026 2.31 2.39 2.29 2.34 2.34 3,530,414
Aug 14, 2026 2.32 2.33 2.27 2.32 2.32 1,762,685
Aug 13, 2026 2.37 2.39 2.32 2.34 2.34 2,315,188
Aug 12, 2026 2.41 2.46 2.35 2.35 2.35 2,569,147
Aug 11, 2026 2.42 2.45 2.31 2.43 2.43 3,031,984
Aug 10, 2026 2.45 2.49 2.38 2.40 2.40 2,696,711
Aug 7, 2026 2.44 2.48 2.29 2.47 2.47 3,085,741
Aug 6, 2026 1.96 2.44 1.96 2.36 2.36 4,890,832
Aug 5, 2026 2.52 2.52 2.40 2.45 2.45 3,974,293
Aug 4, 2026 2.33 2.52 2.32 2.49 2.49 3,908,893
Aug 3, 2026 2.29 2.34 2.22 2.33 2.33 2,053,054
Jul 31, 2026 2.32 2.35 2.25 2.31 2.31 2,767,972
Jul 30, 2026 2.32 2.40 2.29 2.34 2.34 2,464,426
Jul 29, 2026 2.38 2.42 2.29 2.32 2.32 2,476,278
Jul 28, 2026 2.24 2.35 2.17 2.34 2.34 2,680,219
Jul 27, 2026 2.30 2.38 2.16 2.23 2.23 2,957,356
Jul 24, 2026 2.30 2.35 2.24 2.29 2.29 1,681,849
Jul 23, 2026 2.21 2.35 2.19 2.30 2.30 2,708,450
Jul 22, 2026 2.36 2.37 2.19 2.25 2.25 3,601,885
Jul 21, 2026 2.33 2.40 2.26 2.38 2.38 2,348,814
Jul 20, 2026 2.40 2.42 2.26 2.33 2.33 3,095,660
Jul 17, 2026 2.22 2.40 2.19 2.39 2.39 2,431,579
Jul 16, 2026 2.20 2.25 2.17 2.24 2.24 2,736,852
Jul 15, 2026 2.11 2.21 2.04 2.20 2.20 4,408,666
Jul 14, 2026 2.20 2.22 2.10 2.12 2.12 1,541,127
Jul 13, 2026 2.20 2.22 2.14 2.17 2.17 1,705,614
Jul 10, 2026 2.25 2.25 2.14 2.22 2.22 2,299,214
Jul 9, 2026 2.28 2.28 2.21 2.25 2.25 1,465,319
Jul 8, 2026 2.34 2.35 2.22 2.27 2.27 4,050,818
Jul 7, 2026 2.32 2.44 2.26 2.37 2.37 4,745,125
Jul 6, 2026 2.30 2.42 2.30 2.32 2.32 2,219,283
Jul 2, 2026 2.35 2.44 2.27 2.32 2.32 2,630,031
Jul 1, 2026 2.37 2.44 2.33 2.34 2.34 2,408,788
Jun 30, 2026 2.68 2.68 2.37 2.40 2.40 5,191,551
Jun 29, 2026 2.55 2.67 2.48 2.64 2.64 4,632,132
Jun 26, 2026 2.27 2.55 2.27 2.55 2.55 39,463,853
Jun 25, 2026 2.23 2.38 2.23 2.29 2.29 3,395,327
Jun 24, 2026 2.18 2.27 2.18 2.22 2.22 2,823,421
Jun 23, 2026 2.10 2.23 2.06 2.16 2.16 2,774,239
Jun 22, 2026 1.99 2.15 1.99 2.15 2.15 3,035,727
Jun 18, 2026 2.04 2.10 1.98 2.01 2.01 3,927,187
Jun 17, 2026 1.95 2.09 1.95 2.04 2.04 2,622,399
Jun 16, 2026 1.95 2.02 1.92 1.95 1.95 1,853,927
Jun 15, 2026 1.95 1.98 1.92 1.96 1.96 2,081,608
Jun 12, 2026 1.89 2.02 1.88 1.92 1.92 2,994,452
Jun 11, 2026 1.88 1.95 1.84 1.89 1.89 2,041,413
Jun 10, 2026 1.85 1.91 1.85 1.88 1.88 1,283,139
Jun 9, 2026 1.88 1.93 1.84 1.88 1.88 1,262,183
Jun 8, 2026 1.93 1.99 1.86 1.88 1.88 1,489,321
Jun 5, 2026 1.90 1.94 1.87 1.91 1.91 1,761,568
Jun 4, 2026 1.84 1.99 1.84 1.90 1.90 1,756,886
Jun 3, 2026 1.84 1.93 1.80 1.85 1.85 2,661,214
Jun 2, 2026 2.09 2.09 1.88 1.89 1.89 3,157,449
Jun 1, 2026 2.17 2.19 2.06 2.07 2.07 1,830,117
May 29, 2026 2.20 2.23 2.14 2.18 2.18 1,617,877
May 28, 2026 2.17 2.27 2.17 2.21 2.21 1,866,698
May 27, 2026 2.05 2.21 2.04 2.17 2.17 1,931,114
May 26, 2026 2.21 2.22 2.04 2.06 2.06 3,074,558
May 22, 2026 2.23 2.29 2.15 2.16 2.16 1,625,337
May 21, 2026 2.11 2.25 2.11 2.23 2.23 1,688,464
May 20, 2026 2.13 2.26 2.13 2.21 2.21 1,700,074
May 19, 2026 2.11 2.15 2.04 2.13 2.13 1,646,459
May 18, 2026 2.22 2.26 2.08 2.14 2.14 2,226,678
May 15, 2026 2.29 2.32 2.21 2.23 2.23 2,117,562
May 14, 2026 2.44 2.44 2.29 2.33 2.33 2,521,321
May 13, 2026 2.41 2.51 2.34 2.44 2.44 3,314,830
May 12, 2026 2.31 2.53 2.25 2.41 2.41 6,253,566
May 11, 2026 2.01 2.47 2.00 2.31 2.31 13,977,932
May 8, 2026 1.69 2.00 1.64 2.00 2.00 7,018,739
May 7, 2026 1.65 1.69 1.52 1.68 1.68 5,024,677
May 6, 2026 1.66 1.66 1.60 1.60 1.60 2,210,354
May 5, 2026 1.60 1.65 1.56 1.65 1.65 1,588,385
May 4, 2026 1.63 1.67 1.59 1.60 1.60 1,095,620
May 1, 2026 1.59 1.66 1.57 1.63 1.63 1,398,160
Apr 30, 2026 1.58 1.63 1.56 1.61 1.61 1,160,391
Apr 29, 2026 1.66 1.66 1.55 1.55 1.55 1,607,784
Apr 28, 2026 1.69 1.72 1.66 1.66 1.66 990,047
Apr 27, 2026 1.68 1.76 1.67 1.69 1.69 1,920,482
Apr 24, 2026 1.67 1.70 1.61 1.68 1.68 1,931,996
Apr 23, 2026 1.83 1.85 1.67 1.68 1.68 2,208,152
Apr 22, 2026 1.85 1.91 1.80 1.82 1.82 1,401,918
Apr 21, 2026 1.85 1.89 1.79 1.83 1.83 1,402,013
Apr 20, 2026 1.87 1.88 1.80 1.84 1.84 1,649,963
Apr 17, 2026 1.86 1.95 1.85 1.87 1.87 3,142,111
Apr 16, 2026 1.86 1.89 1.81 1.84 1.84 1,969,267
Apr 15, 2026 1.75 1.86 1.74 1.86 1.86 2,135,662
Apr 14, 2026 1.70 1.79 1.70 1.75 1.75 1,257,529
Apr 13, 2026 1.70 1.74 1.69 1.71 1.71 838,359
Apr 10, 2026 1.77 1.80 1.70 1.72 1.72 1,368,261
Apr 9, 2026 1.65 1.84 1.65 1.76 1.76 3,948,321
Apr 8, 2026 1.65 1.70 1.62 1.67 1.67 2,303,383
Apr 7, 2026 1.59 1.65 1.55 1.60 1.60 1,888,348
Apr 6, 2026 1.59 1.64 1.58 1.59 1.59 1,587,079
Apr 2, 2026 1.61 1.63 1.58 1.59 1.59 2,316,350
Apr 1, 2026 1.59 1.71 1.55 1.64 1.64 2,904,323
Mar 31, 2026 1.52 1.59 1.52 1.56 1.56 1,754,933
Mar 30, 2026 1.65 1.66 1.49 1.51 1.51 3,358,384
Mar 27, 2026 1.62 1.65 1.60 1.65 1.65 1,714,654
Mar 26, 2026 1.66 1.70 1.58 1.63 1.63 3,670,844
Mar 25, 2026 1.72 1.77 1.65 1.68 1.68 2,731,167
Mar 24, 2026 1.63 1.77 1.63 1.72 1.72 2,701,283
Mar 23, 2026 1.56 1.66 1.55 1.64 1.64 1,853,359
Mar 20, 2026 1.62 1.62 1.51 1.56 1.56 6,680,626
Mar 19, 2026 1.55 1.64 1.54 1.62 1.62 1,456,881
Mar 18, 2026 1.61 1.64 1.55 1.56 1.56 1,395,000
Mar 17, 2026 1.60 1.67 1.58 1.62 1.62 1,308,969
Mar 16, 2026 1.71 1.74 1.61 1.61 1.61 2,045,206
Mar 13, 2026 1.70 1.79 1.66 1.69 1.69 2,245,545
Mar 12, 2026 1.70 1.72 1.66 1.72 1.72 1,928,561
Mar 11, 2026 1.66 1.72 1.61 1.72 1.72 2,423,785
Mar 10, 2026 1.72 1.77 1.61 1.66 1.66 3,522,091
Mar 9, 2026 1.69 1.78 1.66 1.68 1.68 3,642,071
Mar 6, 2026 1.64 1.76 1.58 1.71 1.71 4,901,176
Mar 5, 2026 1.54 1.75 1.45 1.64 1.64 4,156,723
Mar 4, 2026 1.62 1.66 1.57 1.63 1.63 2,510,134
Mar 3, 2026 1.51 1.64 1.49 1.61 1.61 3,908,202
Mar 2, 2026 1.42 1.58 1.42 1.56 1.56 2,741,013
Feb 27, 2026 1.50 1.50 1.44 1.47 1.47 1,258,425
Feb 26, 2026 1.48 1.53 1.42 1.50 1.50 1,916,219
Feb 25, 2026 1.53 1.56 1.47 1.50 1.50 2,085,030
Feb 24, 2026 1.51 1.62 1.48 1.48 1.48 2,535,518
Feb 23, 2026 1.52 1.56 1.47 1.51 1.51 2,404,810
Feb 20, 2026 1.50 1.51 1.44 1.47 1.47 2,257,179
Feb 19, 2026 1.42 1.52 1.40 1.52 1.52 3,378,751
Feb 18, 2026 1.31 1.37 1.30 1.32 1.32 1,708,034
Feb 17, 2026 1.32 1.34 1.29 1.32 1.32 995,337
Feb 13, 2026 1.31 1.35 1.28 1.31 1.31 1,106,488
Feb 12, 2026 1.36 1.37 1.29 1.31 1.31 1,665,758
Feb 11, 2026 1.30 1.39 1.28 1.37 1.37 2,144,095
Feb 10, 2026 1.23 1.33 1.23 1.31 1.31 2,691,046
Feb 9, 2026 1.23 1.24 1.17 1.20 1.20 1,736,037
Feb 6, 2026 1.20 1.27 1.20 1.23 1.23 2,085,891
Feb 5, 2026 1.33 1.40 1.17 1.18 1.18 6,926,324
Feb 4, 2026 1.29 1.32 1.18 1.27 1.27 3,758,369
Feb 3, 2026 1.25 1.28 1.19 1.28 1.28 2,888,957
Feb 2, 2026 1.15 1.28 1.13 1.25 1.25 3,919,081
Jan 30, 2026 1.29 1.33 1.10 1.16 1.16 17,102,727
Jan 29, 2026 1.53 1.54 1.42 1.44 1.44 1,641,224
Jan 28, 2026 1.71 1.71 1.50 1.50 1.50 2,459,349
Jan 27, 2026 1.57 1.71 1.55 1.71 1.71 2,484,350
Jan 26, 2026 1.71 1.71 1.57 1.57 1.57 2,570,617
Jan 23, 2026 1.78 1.79 1.65 1.70 1.70 3,460,603
Jan 22, 2026 1.55 1.83 1.52 1.76 1.76 8,330,224
Jan 21, 2026 1.34 1.65 1.33 1.56 1.56 10,503,271
Jan 20, 2026 1.33 1.33 1.25 1.31 1.31 1,651,532
Jan 16, 2026 1.28 1.41 1.26 1.37 1.37 2,909,365
Jan 15, 2026 1.24 1.29 1.23 1.28 1.28 1,409,746
Jan 14, 2026 1.21 1.27 1.21 1.24 1.24 1,592,565
Jan 13, 2026 1.19 1.23 1.18 1.20 1.20 1,529,921
Jan 12, 2026 1.15 1.18 1.11 1.18 1.18 1,737,536
Jan 9, 2026 1.18 1.20 1.17 1.17 1.17 1,202,573
Jan 8, 2026 1.15 1.21 1.14 1.18 1.18 1,202,294
Jan 7, 2026 1.14 1.23 1.14 1.17 1.17 2,063,344
Jan 6, 2026 1.16 1.17 1.12 1.14 1.14 1,173,446
Jan 5, 2026 1.15 1.17 1.12 1.14 1.14 1,296,004
Jan 2, 2026 1.16 1.16 1.11 1.14 1.14 902,605
Dec 31, 2025 1.14 1.16 1.12 1.15 1.15 1,791,175
Dec 30, 2025 1.16 1.18 1.13 1.15 1.15 2,346,110
Dec 29, 2025 1.20 1.22 1.15 1.17 1.17 1,547,101
Dec 26, 2025 1.23 1.24 1.19 1.23 1.23 896,691
Dec 24, 2025 1.21 1.24 1.20 1.23 1.23 748,024
Dec 23, 2025 1.23 1.24 1.17 1.21 1.21 1,776,335
Dec 22, 2025 1.17 1.31 1.16 1.22 1.22 2,894,059
Dec 19, 2025 1.17 1.20 1.11 1.17 1.17 3,454,925
Dec 18, 2025 1.15 1.25 1.14 1.18 1.18 1,921,699
Dec 17, 2025 1.18 1.22 1.14 1.15 1.15 2,171,722
Dec 16, 2025 1.22 1.25 1.17 1.20 1.20 1,695,288
Dec 15, 2025 1.31 1.33 1.23 1.23 1.23 1,298,121
Dec 12, 2025 1.32 1.35 1.30 1.30 1.30 1,080,696
Dec 11, 2025 1.31 1.36 1.30 1.32 1.32 1,062,857
Dec 10, 2025 1.33 1.36 1.30 1.32 1.32 1,248,820
Dec 9, 2025 1.39 1.40 1.29 1.31 1.31 2,018,195
Dec 8, 2025 1.42 1.48 1.35 1.39 1.39 2,080,494
Dec 5, 2025 1.42 1.45 1.38 1.40 1.40 1,554,208
Dec 4, 2025 1.41 1.43 1.38 1.42 1.42 1,440,121
Dec 3, 2025 1.34 1.41 1.33 1.40 1.40 1,531,642
Dec 2, 2025 1.37 1.40 1.34 1.34 1.34 772,372
Dec 1, 2025 1.38 1.40 1.34 1.36 1.36 1,299,292
Nov 28, 2025 1.43 1.47 1.40 1.43 1.43 726,136
Nov 26, 2025 1.41 1.44 1.39 1.43 1.43 772,357
Nov 25, 2025 1.44 1.44 1.37 1.41 1.41 1,168,210
Nov 24, 2025 1.35 1.42 1.34 1.42 1.42 999,291
Nov 21, 2025 1.32 1.35 1.28 1.34 1.34 1,860,327
Nov 20, 2025 1.44 1.51 1.32 1.32 1.32 2,760,802
Nov 19, 2025 1.48 1.52 1.42 1.45 1.45 1,604,869
Nov 18, 2025 1.45 1.48 1.43 1.47 1.47 1,339,495
Nov 17, 2025 1.47 1.47 1.42 1.46 1.46 1,705,611
Nov 14, 2025 1.38 1.50 1.36 1.49 1.49 2,234,967
Nov 13, 2025 1.51 1.53 1.43 1.44 1.44 1,533,308
Nov 12, 2025 1.56 1.64 1.47 1.54 1.54 4,316,703
Nov 11, 2025 1.39 1.59 1.36 1.56 1.56 3,637,074
Nov 10, 2025 1.25 1.45 1.25 1.42 1.42 3,915,804
Nov 7, 2025 1.39 1.42 1.18 1.25 1.25 4,949,943
Nov 6, 2025 1.40 1.52 1.39 1.43 1.43 2,938,055
Nov 5, 2025 1.33 1.40 1.31 1.38 1.38 2,727,216
Nov 4, 2025 1.33 1.39 1.32 1.33 1.33 1,277,771
Nov 3, 2025 1.38 1.39 1.35 1.36 1.36 1,911,413
Oct 31, 2025 1.35 1.40 1.34 1.38 1.38 1,111,291
Oct 30, 2025 1.34 1.37 1.30 1.34 1.34 1,200,327
Oct 29, 2025 1.37 1.37 1.31 1.33 1.33 2,224,857
Oct 28, 2025 1.39 1.41 1.36 1.37 1.37 1,459,637
Oct 27, 2025 1.45 1.48 1.39 1.39 1.39 2,099,753
Oct 24, 2025 1.42 1.46 1.40 1.42 1.42 1,010,036
Oct 23, 2025 1.40 1.44 1.40 1.40 1.40 789,598
Oct 22, 2025 1.44 1.45 1.36 1.39 1.39 2,202,343
Oct 21, 2025 1.52 1.53 1.44 1.44 1.44 1,563,633
Oct 20, 2025 1.44 1.53 1.43 1.52 1.52 1,880,034
Oct 17, 2025 1.44 1.46 1.39 1.42 1.42 1,695,680
Oct 16, 2025 1.54 1.58 1.45 1.47 1.47 3,009,042
Oct 15, 2025 1.49 1.53 1.47 1.53 1.53 2,239,696
Oct 14, 2025 1.44 1.49 1.42 1.46 1.46 1,836,858
Oct 13, 2025 1.51 1.51 1.40 1.44 1.44 2,877,240
Oct 10, 2025 1.66 1.66 1.45 1.49 1.49 4,923,730
Oct 9, 2025 1.45 1.65 1.45 1.64 1.64 5,667,750
Oct 8, 2025 1.52 1.54 1.41 1.43 1.43 3,069,768
Oct 7, 2025 1.59 1.61 1.48 1.52 1.52 4,060,311
Oct 6, 2025 1.45 1.55 1.43 1.55 1.55 3,598,099
Oct 3, 2025 1.40 1.46 1.38 1.41 1.41 2,268,456
Oct 2, 2025 1.42 1.45 1.35 1.38 1.38 2,038,779
Oct 1, 2025 1.35 1.45 1.34 1.41 1.41 2,795,003
Sep 30, 2025 1.37 1.39 1.28 1.35 1.35 2,604,109
Sep 29, 2025 1.39 1.41 1.37 1.39 1.39 2,020,541
Sep 26, 2025 1.35 1.42 1.29 1.40 1.40 3,554,435
Sep 25, 2025 1.31 1.37 1.27 1.34 1.34 3,736,089
Sep 24, 2025 1.22 1.34 1.22 1.33 1.33 3,541,235

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Lexicon Pharmaceuticals, Inc. Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at LXRX, per a recent SEC DEF 14A filing. We estimate that the median employee at LEXICON PHARMACEUTICALS, INC. is paid $304,524.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation